Indaptus Therapeutics/$INDP

1D1W1MYTD1Y5YMAX

About Indaptus Therapeutics

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Ticker
$INDP
Sector
Health
Primary listing
NASDAQ
Employees
5
Headquarters
New York, United States
Website
indaptusrx.com

INDP Metrics

BasicAdvanced
$532M
-
-$0.47
1.18
-

Bulls say / Bears say

The June private placement raised approximately $12 million, leaving $11.6 million in cash, cash equivalents and short-term investments at June 30, 2026; management said this liquidity should fund activities through the second quarter of 2027 under current plans. (SEC filing; SEC 10-Q)
Cost discipline has materially reduced cash-burn pressure: first-half research and development expense fell 83% year over year to approximately $0.9 million, while the net loss declined to approximately $4.3 million from $9.8 million. (SEC filing)
Strategic optionality has broadened beyond Decoy20, with management evaluating collaborations, investments, acquisitions and other business combinations while beginning a research collaboration in neurological disorders and sleep. A successful transaction or validated new program could provide a new value path for the public company. (SEC filing)
Decoy20’s development has effectively been wound down: enrollment in the combination study stopped, no participants remain in active Decoy20 studies, and the company currently has no active clinical-development programs. This removes near-term clinical catalysts and leaves the investment case dependent on strategic alternatives. (SEC filing)
Material dilution is a major risk: the June financing issued 20 million shares at $0.60, while the August ATM agreement permits up to $100 million of additional common-stock sales. The share count rose to 133.2 million by June 30, 2026, versus 2.2 million at year-end 2025. (SEC filing; SEC filing)
Indaptus remains loss-making and financing-dependent: it reported a $4.3 million net loss and $8.9 million of operating cash use for the first half of 2026, and management states that additional financing will be needed to achieve its objectives. (SEC 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 11 Sept 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.